ST. PAUL, Minn.--(BUSINESS WIRE)--EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that it expects study results from ongoing clinical trials of the company’s VBLOC™ vagal blocking therapy to be presented at 3:00 PM ET on June 19, 2008 during a plenary session of the 25th annual meeting of the American Society for Metabolic and Bariatric Surgery, being held June 15–20 in Washington, D.C. The oral presentation will include interim 12-month and updated 9-month excess weight loss, or EWL, endpoints from EnteroMedics’ VBLOC-RF2 feasibility study for obesity therapy as well as a preliminary report on the Company’s VBLOC-RC (rechargeable) device.
